ClinicalTrials.gg
Active, not recruitingNCT06896656STARUpdated Nov 17, 2026

Improving Social Connectedness Through Digital Health to Enhance Recovery From OUD Among the Justice Involved Population

An interventional study of Marigold Mobile Peer Support Intervention and Resources in Loneliness and Opioid Use Disorder, sponsored by Rhode Island Hospital. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Rhode Island Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Nov 17, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,223 studies in Opioid-Related Disorders with a site in United States — 246 open to participants now, 316 under way, 18 of them phase 3. Opioid-Related Disorders · United States.

Planned enrollment
417th of 1,098
90 · median 56
Started
2025
with 88 others
No phase
571 of 1,223
133 open now
Primary completion
2026-11
later than 73 of 315 live
Registered
1,104th of 1,223
by date

Among the 1,223 studies in Opioid-Related Disorders with a site in United States, this one is the 417th largest by planned enrollment of the 1,098 interventional ones that give a count, is one of 89 that started in 2025, is one of 571 with no phase, reaches primary completion later than 73 of the 315 other live ones, and was the 1,104th registered.

Opioid-Related Disorders

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

246 of the 1,223 studies in Opioid-Related Disorders with a site in United States are open now. Recruiting first, the newest first:

241 more — sign in →

All 246 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,223 studies in Opioid-Related Disorders with a site in United States, or all of them as a file.
02

Study summary

People with a history of Opioid Use Disorder and criminal justice involvement are more likely to experience loneliness following release from jail/prison leading to negative outcomes such as treatment dropout and increased substance use. Providing peer recovery support, particularly through a highly accessible, digital health platform, is a potential way to decrease loneliness in this population. The current study seeks to test whether a mobile peer recovery support app, delivered to individuals with a recent history of taking medication for opioid use disorder while in jail/prison, will improve outcomes for this vulnerable population.

Read the detailed description

Individuals with criminal justice involvement experience elevated rates of Opioid Use Disorder (OUD) and are at significantly higher risk of death from opioid overdose in the first year following release from jail/prison. Medications for OUD (MOUD) are an evidence-based approach to treating OUD and offer extensive benefits including lowering rates of mortality, illicit opioid use, HIV transmission, violent crime, and arrest. While many correctional settings have started to implement MOUD, there are significant challenges to continuing medication/treatment while transitioning back to the community. Intersectional stigma related to addiction and history of incarceration is associated with greater difficulties with reintegration, increased isolation, and heightened feelings of loneliness. Lack of social connectedness further serves as a risk factor for decreased retention in treatment, discontinuation of MOUD, and a return to substance use. Peer support is a key component of many evidence-based OUD recovery programs. When used in conjunction with MOUD, it has the potential to improve perceived social support, self-efficacy, and treatment engagement. However, access to live peer support has been challenged by COVID restrictions, highlighting a critical need for digital health platforms to deliver peer support. The Marigold Mobile Peer Support ("MPS") App is a dedicated, secure, mobile application that employs structured, live peer moderation to guide text-based conversations with groups of participants and behind-the-scenes natural language processing (NLP) to automatically identify "red flag" content within peer chats. While initial work demonstrates the utility of deploying the MPS App in outpatient treatment settings for OUD, it has yet to be tested in correctional settings or among justice-involved populations. The goal of the proposed application is to advance evidence-based and scalable treatments for OUD, by decreasing loneliness and enhancing perceived social support via novel application of an established mobile app among individuals with a history of engaging in MOUD while in jail/prison. The study will be accomplished through two primary aims: (1) develop an implementation manual to guide delivery of the MPS App for those with a recent (past year) history of engaging in MOUD while in jail/prison by conducting in-depth interviews with prospective app users and other key stakeholders; and (2) conduct a randomized controlled trial to assess feasibility, acceptability, and preliminary efficacy of the MPS App relative to enhanced treatment-as-usual among individuals with a recent (past year) history of engaging in MOUD while in jail/prison. Findings from this study will be used to develop a R01 application to conduct a fully-powered Hybrid Type 1 Effectiveness-Implementation study.

03

Conditions studied

  • Loneliness
  • Opioid Use Disorder

Keywords

  • Mobile Health
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18+ years of age
  • history of being prescribed medication for opioid use disorder (MOUD) while in jail or prison
  • most recently released from prison with the past two years
  • self-reported recovery for an Opioid Use Disorder (OUD)
  • able to understand and speak English and to provide written and verbal consent
  • anticipated discharge from jail/prison within 3 months if currently incarcerated

Exclusion criteria

Exclusion Criteria:

  • N/A
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    MPS App

    This is the experimental arm. Participants assigned to this arm will receive access to the Marigold Health App (MPS) intervention. N = 60 participants will be assigned to this arm.

    Behavioral: Marigold Mobile Peer Support Intervention

  • Active comparator
    Enhanced Treatment as Usual

    This is the active comparator arm. Participants assigned to this arm will receive enhanced treatment as usual. N = 30 participants will be assigned to this arm.

    Behavioral: Resources

Interventions

  • BehavioralMarigold Mobile Peer Support Intervention

    The MPS App is a secure platform that allows text-based peer support for individuals in recovery from OUD. Participants assigned to this condition will be enrolled on a rolling basis into a peer support group on the app. All participants will receive onboarding assistance and will have access to the app for 6 months. The app will include live moderation from a certified Peer Recovery Support Specialist and trained research assistants. Moderators will begin discussions with prompts and regulate the flow of conversation with standardized text language. Moderators will be able to respond in real-time to malicious messages or other "flags" that could impact participant safety. Built in natural language processing algorithms will also detect language requiring intervention and automatically alter the moderators and on-call clinicians.

  • BehavioralResources

    A list of online peer support and mental health resources, drawn from SAMSHA and equivalent websites, will be provided to all participants, as an enhanced adjunct to their standard recovery plans.

06

What researchers measure

Primary outcomes

  1. Social Support

    Perceived social support will be assessed with the Multidimensional Scale of Perceived Social Support (MSPSS). This assessment is psychometrically sound, with adequate reliability and validity, and measures perceived social support from family, friends, and significant others among adults. Scores are averaged and range from 1 to 7, with 1 signifying the lowest level of social support and 7 signifying the highest.

    Time frame: Baseline, 1, 3, and 6 months.

  2. Loneliness

    Loneliness will be assessed with the 20-item UCLA Loneliness scale. Scores range from 20 to 80, where higher scores indicate greater loneliness.

    Time frame: Baseline, 1, 3, and 6 months.

Secondary outcomes

  1. Substance Use

    Self-reported substance use will be assessed with the Timeline Follow-Back interview and biochemically confirmed with Urine Drug Screens. Substance use will be operationalized as the percentage of days positive for drug use (separate by drug class) in between assessments.

    Time frame: Baseline, 1, 3, and 6 months.

  2. Engagement in Medications for Opioid Use Disorder (MOUD)

    Self-reported engagement in MOUD will be assessed with a Timeline Follow-Back interview and biochemically confirmed with Urine Drug Screens. Engagement in MOUD will be operationalized as the percentage of days positive for MOUD administration in between assessments.

    Time frame: Baseline, 1, 3, and 6 months.

Other outcomes

  1. Demographics

    Using the PhenX toolkit, basic demographic data and social determinants of health will be collected. In addition, prior and current history with the criminal justice system will be assessed with the Adult Incarceration Module of the National Survey on Drug Use and Health (NSDUH) 2014 Questionnaire.

    Time frame: Baseline

  2. Treatment Received

    The Treatment Services Review will be administered to assess receipt of case management, psychiatric, peer recovery coaching, and other treatment services, including utilization of MOUD. At follow-up interviews, participants will be asked about the services received since the previous interview.

    Time frame: Baseline, 1, 3, and 6 months.

  3. Quality of Life

    The Quality of Life Enjoyment and Satisfaction Questionnaire Short Form, a 16-item questionnaire with sound psychometric properties, will be administered to assess quality of life. Scores range from 0 to 100, with higher scores indicating greater enjoyment and satisfaction.

    Time frame: Baseline, 1, 3, and 6 months.

  4. Wellbeing

    The World Health Organization-Five Well-Being Index (WHO-5) will be administered to assess wellbeing. This 5-item questionnaire is a widely used and valid tool for assessing wellbeing. Scores range from 0 to 100, with 0 representing the worst possible wellbeing and 100 representing the best possible wellbeing.

    Time frame: Baseline, 1, 3, and 6 months.

  5. Depressive Symptoms

    Depressive symptoms will be assessed with the Patient Health Questionnaire-2 (PHQ-2). This measure consists of 2 items with high sensitivity, specificity, and discriminant validity for diagnosing major depression. Scores range from 0 to 6. A score of 3 or greater indicates major depression disorder is likely.

    Time frame: Baseline, 1, 3, and 6 months.

  6. Anxiety Symptoms

    Anxiety symptoms will be assessed with the Generalized Anxiety Disorder 2-Item (GAD-2). This measure consists of 2 items and has well established accuracy for identifying clinically significant anxiety symptoms and tracking treatment progress outcomes. Scores range from 0 to 6. A score of 3 or greater indicates a high likelihood of generalized anxiety disorder diagnosis.

    Time frame: Baseline, 1, 3, and 6 months.

  7. Perceived Stress

    The Perceived Stress Scale (PSS-10) will be administered to assess perceived stress in the past month. The PSS-10 consists of 10 items and is psychometrically sound. Scores range from 0 to 40, with 40 representing the highest possible perceived stress.

    Time frame: Baseline, 1, 3, and 6 months.

  8. Number of Days of App Use

    The number of days participants use the Marigold Health app will be extracted from the app as indices of app engagement.

    Time frame: 6 months

  9. Number of Messages Sent in App

    The number of messages a participant sends in the Marigold Health app will be extracted from the app as an indices of app engagement.

    Time frame: 6 months

  10. System Usability Scale

    The System Usability Scale will be administered to participants in the treatment arm. This assessment measures perceived usability of digital systems. Scores range from 0 to 100, with 100 representing high perceived usability. These scores will be used as indices of app satisfaction.

    Time frame: 6 months

  11. Client Satisfaction Questionnaire

    The Client Satisfaction Questionnaire will be administered to participants in the treatment arm. This measure of intervention satisfaction consists of 8 items. Scores range from 8 to 32, with higher scores indicting higher satisfaction. These scores will serve as indices of app satisfaction.

    Time frame: 6 months

  12. Qualitative Exit Interview

    Qualitative exit interviews will be conducted with a subset of participants (n = 20) assigned to the treatment arm. The interviews will be used to collect in-depth feedback about the intervention.

    Time frame: 6 months

  13. Number of Flagged Messages

    The number of messages flagged in the Marigold Health app will be extracted from the app. This will serve as indices of safety of the app.

    Time frame: 6 months

  14. Number of Crisis Interventions

    The number of crisis interventions clinicians administer to participants using the Marigold Health app will be extracted from the app. This will serve as indices of app safety.

    Time frame: 6 months

  15. Time Spent Onboarding App Users

    The amount of time required for research staff to onboard users to the Marigold Health app will be recorded. This will serve as indices of intervention scalability.

    Time frame: 6 months

  16. Clinician Time Spent on Crisis Managment

    The amount of time it takes clinicians to manage emergent crises on the Marigold Health app will be recorded. This will serve as indices of intervention scalability.

    Time frame: 6 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Nov 2026, 20 months after the start.

Of 465 non-industry interventional studies with no phase under Opioid-Related Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 47. This study's planned 20 months is below that.

Counting every sponsor, half of 496 studies reached it within 29 months; a quarter within 13 and three quarters within 46.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Oct 2026 → Nov 2026 and completion Nov 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2025
First posted
Mar 26, 2025
StartActual
Mar 17, 2025
Primary completionEst.
Nov 30, 2026was Oct 2026
CompletionEst.
Dec 31, 2026was Nov 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 31, 2026→Nov 30, 2026
Nov 17, 2026
Study completion
Nov 30, 2026→Dec 31, 2026
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Primary completion Oct 31, 2026→Nov 30, 2026
    Study completion Nov 30, 2026→Dec 31, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06896656
Responsible party
Sponsor
First posted
Mar 26, 2025
Start date
Mar 17, 2025
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 17, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion